pharmaphorum January 24, 2025
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates.
The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation – show that the combined GLP-1 and amylin agonist achieved up to 22% weight loss at 36 weeks.
The phase 1b/2a trial in 125 people with obesity or overweight combined single ascending dose, multiple ascending dose, and dose-response assessments and looked at three different doses of amycretin; namely, 1.25mg, 5mg, and 20mg.
It also showed that the drug was well tolerated, with side effects mainly gastrointestinal complaints...
Today's Sponsors
Today's Sponsor